Patients with fatty liver disease may experience additional symptoms that complicate the clinical picture
10.1186/s13098-022-00924-8 Summary Keywords GLP-1 receptor agonists, DPP-4 inhibitors, FAERS, adverse events, biliary disorders, pharmacovigilance Citation He L, Li J, Cheng X, Luo L and Huang Y (2025) Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis
Unlike semaglutide, orforglipron is a small-molecule drug, which means it can be taken at any time of day, with or without food, and without the strict water-only morning routine
ROS-induced NLRP3 inflammasome priming and activation mediate PCB 118- induced pyroptosis in endothelial cells
are employees of or consultants for ConfometRx